212 related articles for article (PubMed ID: 32522059)
21. CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies.
Hu Y; Li J; Ni F; Yang Z; Gui X; Bao Z; Zhao H; Wei G; Wang Y; Zhang M; Hong R; Wang L; Wu W; Mohty M; Nagler A; Chang AH; van den Brink MRM; Li MD; Huang H
Nat Commun; 2022 Sep; 13(1):5313. PubMed ID: 36085303
[TBL] [Abstract][Full Text] [Related]
22. Born to survive: how cancer cells resist CAR T cell therapy.
Lemoine J; Ruella M; Houot R
J Hematol Oncol; 2021 Nov; 14(1):199. PubMed ID: 34809678
[TBL] [Abstract][Full Text] [Related]
23. Learning from the microbes: exploiting the microbiome to enforce T cell immunotherapy.
Staudt S; Ziegler-Martin K; Visekruna A; Slingerland J; Shouval R; Hudecek M; van den Brink M; Luu M
Front Immunol; 2023; 14():1269015. PubMed ID: 37799719
[TBL] [Abstract][Full Text] [Related]
24. Chimeric antigen receptors: "CARs" in the fast lane for rheumatology.
Johnson NM; Koumpouras F
Curr Opin Rheumatol; 2024 May; 36(3):176-183. PubMed ID: 38517338
[TBL] [Abstract][Full Text] [Related]
25. Early cytopenias and infections following chimeric antigen receptor T-Cell therapy for hematologic malignancies.
McGann M; Velayati A; Roubal K; Granger K; Davis JA; Gaffney KJ; Weeda E; Hashmi H
Leuk Lymphoma; 2023 Sep; 64(9):1592-1595. PubMed ID: 37287328
[No Abstract] [Full Text] [Related]
26. Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy.
Johnson PC; Dhawale T; Newcomb RA; Amonoo HL; Lavoie MW; Vaughn D; Karpinski K; El-Jawahri A
Blood Adv; 2023 Jul; 7(14):3541-3550. PubMed ID: 36995091
[TBL] [Abstract][Full Text] [Related]
27. Emerging Biomarkers for Monitoring Chimeric Antigen Receptor T-Cell Therapy.
Mamo T; Dreyzin A; Stroncek D; McKenna DH
Clin Chem; 2024 Jan; 70(1):116-127. PubMed ID: 38175598
[TBL] [Abstract][Full Text] [Related]
28. Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies.
Baguet C; Larghero J; Mebarki M
Blood Adv; 2024 Jan; 8(2):337-342. PubMed ID: 38052048
[TBL] [Abstract][Full Text] [Related]
29. Predicting CAR-T cell Immunotherapy Success through ImmunoPET.
Volpe A; Nagle VL; Lewis JS; Ponomarev V
Clin Cancer Res; 2021 Feb; 27(4):911-912. PubMed ID: 33328345
[TBL] [Abstract][Full Text] [Related]
30. Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy.
Bulliard Y; Andersson BS; Baysal MA; Damiano J; Tsimberidou AM
J Hematol Oncol; 2023 Oct; 16(1):108. PubMed ID: 37880715
[TBL] [Abstract][Full Text] [Related]
31. Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives.
Levstek L; Janžič L; Ihan A; Kopitar AN
Front Immunol; 2024; 15():1378944. PubMed ID: 38558801
[TBL] [Abstract][Full Text] [Related]
32. Chimeric Antigen Receptor-T Cell Therapy Decreases Distant Metastasis and Inhibits Local Recurrence Post-surgery in Mice.
Li D; Jiang L; Zhou W; Huang Y; Yang Y; Li J; Yang J; Wang F; Li J; Zhang Y; Yan F; Gao H; Guo X; Xu Q; Tan S; Wei YQ; Wang W
Hum Gene Ther; 2023 Dec; 34(23-24):1248-1256. PubMed ID: 37917093
[TBL] [Abstract][Full Text] [Related]
33. Digital PCR Improves Sensitivity and Quantification in Monitoring CAR-T Cells in B Cell Lymphoma Patients.
de la Iglesia-San Sebastián I; Carbonell D; Bastos-Oreiro M; Pérez-Corral A; Bailén R; Chicano M; Muñiz P; Monsalvo S; Escudero-Fernández A; Oarbeascoa G; Fernández-Caldas P; Gómez-Centurión I; Pion M; Gayoso J; Anguita J; Kwon M; Díez-Martín JL; Buño I; Martínez-Laperche C
Transplant Cell Ther; 2024 Mar; 30(3):306.e1-306.e12. PubMed ID: 38184148
[TBL] [Abstract][Full Text] [Related]
34. A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity.
Kim MY; Jayasinghe R; Devenport JM; Ritchey JK; Rettig MP; O'Neal J; Staser KW; Kennerly KM; Carter AJ; Gao F; Lee BH; Cooper ML; DiPersio JF
Nat Commun; 2022 Jun; 13(1):3296. PubMed ID: 35697686
[TBL] [Abstract][Full Text] [Related]
35. Editorial: Predictive short/long-term efficacy biomarkers and resistance mechanisms of CAR-T immunotherapy treatment.
Cheng J; Jin J; Chen L
Front Immunol; 2023; 14():1206441. PubMed ID: 37325665
[No Abstract] [Full Text] [Related]
36. Intrinsic tumor resistance to CAR T cells is a dynamic transcriptional state that is exploitable with low-dose radiation.
Kim AB; Chou SY; Kang S; Kwon E; Inkman M; Szymanski J; Andruska N; Colgan C; Zhang J; Yang JC; Singh N; DeSelm CJ
Blood Adv; 2023 Sep; 7(18):5396-5408. PubMed ID: 37093643
[TBL] [Abstract][Full Text] [Related]
37. Role of bridging therapy during chimeric antigen receptor T cell therapy.
Bhaskar ST; Dholaria BR; Sengsayadeth SM; Savani BN; Oluwole OO
EJHaem; 2022 Jan; 3(Suppl 1):39-45. PubMed ID: 35844303
[TBL] [Abstract][Full Text] [Related]
38. Challenges and strategies associated with CAR-T cell therapy in blood malignancies.
Liu Z; Lei W; Wang H; Liu X; Fu R
Exp Hematol Oncol; 2024 Feb; 13(1):22. PubMed ID: 38402232
[TBL] [Abstract][Full Text] [Related]
39. Author Correction: Deconvolution of clinical variance in CAR-T cell pharmacology and response.
Kirouac DC; Zmurchok C; Deyati A; Sicherman J; Bond C; Zandstra PW
Nat Biotechnol; 2023 Nov; 41(11):1655. PubMed ID: 37188917
[No Abstract] [Full Text] [Related]
40. Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions.
Salaroli A; Spilleboudt C; Bron D; Lewalle P
Curr Opin Oncol; 2020 Sep; 32(5):434-441. PubMed ID: 32796231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
